Insider Trades71 trades
| Date↓ | Side | Ticker↕ | Insider↕ | Role↕ | Shares↕ | Price↕ | Mkt Cap↕ | 52W High↕ | 52W Low↕ | Value↕ | % Chg↕ | Rule↕ | AI View↕ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 16, 2026 | Sell | SRRK | Keith Woods | Chief Operating Officer | 10,220 | $49.57 | $6.7B | -10.28% | +104.69% | $506.7K | -1.62% | — | Buy Now |
| Apr 16, 2026 | Sell | SRRK | Vikas Sinha | Chief Financial Officer | 10,410 | $49.57 | $6.7B | -10.28% | +104.69% | $516.1K | -1.65% | — | Buy Now |
| Apr 16, 2026 | Sell | SRRK | Akshay Vaishnaw | President of R&D | 12,246 | $49.57 | $6.7B | -10.28% | +104.69% | $607.1K | -1.91% | — | Buy Now |
| Apr 16, 2026 | Sell | SRRK | David Hallal | Chief Executive Officer | 30,615 | $49.57 | $6.7B | -10.28% | +104.69% | $1.5M | -1.83% | — | Buy Now |
| Feb 23, 2026 | Sell | SRRK | Mo Qatanani | CHIEF SCIENTIFIC OFFICER | 8,484 | $47.07 | $6.7B | -10.28% | +104.69% | $399.4K | -2.78% | — | Buy Now |
| Feb 17, 2026 | Sell | SRRK | Jing L. Marantz | CHIEF MEDICAL OFFICER | 4,157 | $46.53 | $6.7B | -10.28% | +104.69% | $193.4K | -3.19% | — | Buy Now |
| Feb 17, 2026 | Sell | SRRK | Mo Qatanani | CHIEF SCIENTIFIC OFFICER | 7,989 | $46.53 | $6.7B | -10.28% | +104.69% | $371.7K | -6.95% | — | Buy Now |
| Feb 17, 2026 | Sell | SRRK | Caryn Parlavecchio | CHRO | 9,035 | $46.53 | $6.7B | -10.28% | +104.69% | $420.4K | -5.07% | — | Buy Now |
| Feb 17, 2026 | Sell | SRRK | Junlin Ho | GENERAL COUNSEL | 9,580 | $46.53 | $6.7B | -10.28% | +104.69% | $445.7K | -3.81% | — | Buy Now |
| Jan 22, 2026 | Sell | SRRK | Mo Qatanani | CHIEF SCIENTIFIC OFFICER | 14,898 | $46.71 | $6.7B | -10.28% | +104.69% | $695.9K | -7.49% | — | Buy Now |
| Jan 16, 2026 | Sell | SRRK | Jing L. Marantz | CHIEF MEDICAL OFFICER | 5,798 | $44.48 | $6.7B | -10.28% | +104.69% | $257.9K | -5.71% | — | Buy Now |
| Jan 16, 2026 | Sell | SRRK | Caryn Parlavecchio | CHRO | 6,600 | $44.48 | $6.7B | -10.28% | +104.69% | $293.6K | -4.25% | — | Buy Now |
| Jan 16, 2026 | Sell | SRRK | Junlin Ho | GENERAL COUNSEL | 8,016 | $44.48 | $6.7B | -10.28% | +104.69% | $356.5K | -3.60% | — | Buy Now |
| Jan 16, 2026 | Sell | SRRK | Mo Qatanani | CHIEF SCIENTIFIC OFFICER | 8,406 | $44.48 | $6.7B | -10.28% | +104.69% | $373.9K | -7.71% | — | Buy Now |
| Jan 14, 2026 | Sell | SRRK | Mo Qatanani | CHIEF SCIENTIFIC OFFICER | 26,224 | $31.86 | $6.7B | -10.28% | +104.69% | $835.6K | +0.00% | — | Buy Now |
| Jan 13, 2026 | Sell | SRRK | Keith Woods | Chief Operating Officer | 16,746 | $42.70 | $6.7B | -10.28% | +104.69% | $715.1K | -2.79% | — | Buy Now |
| Jan 13, 2026 | Sell | SRRK | Vikas Sinha | Chief Financial Officer | 16,755 | $42.70 | $6.7B | -10.28% | +104.69% | $715.4K | -2.79% | — | Buy Now |
| Jan 13, 2026 | Sell | SRRK | Akshay Vaishnaw | President of R&D | 20,438 | $42.70 | $6.7B | -10.28% | +104.69% | $872.7K | -3.32% | — | Buy Now |
| Jan 13, 2026 | Sell | SRRK | David Hallal | Chief Executive Officer | 57,450 | $42.70 | $6.7B | -10.28% | +104.69% | $2.5M | -3.59% | — | Buy Now |
| Dec 4, 2025 | Sell | SRRK | Mo Qatanani | CHIEF SCIENTIFIC OFFICER | 272,924 | $33.21 | $6.7B | -10.28% | +104.69% | $9.1M | +0.00% | — | Buy Now |
| Oct 8, 2025 | Sell | SRRK | David Hallal | Chief Executive Officer | 205,000 | $38.69 | $6.7B | -10.28% | +104.69% | $7.9M | -11.36% | — | Buy Now |
| Sep 22, 2025 | Sell | SRRK | Mo Qatanani | CHIEF SCIENTIFIC OFFICER | 3,353 | $30.67 | $6.7B | -10.28% | +104.69% | $102.8K | -2.99% | — | Buy Now |
| Sep 16, 2025 | Sell | SRRK | Mo Qatanani | CHIEF SCIENTIFIC OFFICER | 3,178 | $33.52 | $6.7B | -10.28% | +104.69% | $106.5K | -2.75% | — | Buy Now |
| Aug 18, 2025 | Sell | SRRK | Caryn Parlavecchio | CHRO | 2,178 | $31.17 | $6.7B | -10.28% | +104.69% | $67.9K | -1.38% | — | Buy Now |
| Jul 8, 2025 | Sell | SRRK | Mo Qatanani | CHIEF SCIENTIFIC OFFICER | 24,066 | $34.44 | $6.7B | -10.28% | +104.69% | $828.9K | -17.24% | — | Buy Now |
| Jun 16, 2025 | Sell | SRRK | Mo Qatanani | CHIEF SCIENTIFIC OFFICER | 3,668 | $32.00 | $6.7B | -10.28% | +104.69% | $117.4K | -2.56% | — | Buy Now |
| Jun 16, 2025 | Sell | SRRK | Caryn Parlavecchio | CHRO | 6,186 | $32.00 | $6.7B | -10.28% | +104.69% | $198.0K | -3.78% | — | Buy Now |
| Jun 16, 2025 | Sell | SRRK | Junlin Ho | GENERAL COUNSEL | 7,442 | $32.00 | $6.7B | -10.28% | +104.69% | $238.2K | -3.24% | — | Buy Now |
| May 29, 2025 | Sell | SRRK | Akshay Vaishnaw | President of R&D | 6,750 | $29.72 | $6.7B | -10.28% | +104.69% | $200.6K | -0.54% | — | Buy Now |
| Apr 25, 2025 | Sell | SRRK | Tracey Sacco | Chief Commercial Officer | 10,000 | $21.41 | $6.7B | -10.28% | +104.69% | $214.1K | +0.00% | 10b5-1 | Buy Now |
| Mar 24, 2025 | Sell | SRRK | Tracey Sacco | Chief Commercial Officer | 11,500 | $23.04 | $6.7B | -10.28% | +104.69% | $265.0K | -0.36% | 10b5-1 | Buy Now |
| Mar 24, 2025 | Sell | SRRK | Erin Moore | Interim PFO and PAO | 27,128 | $25.23 | $6.7B | -10.28% | +104.69% | $684.3K | +0.00% | 10b5-1 | Buy Now |
| Mar 10, 2025 | Sell | SRRK | Edward H Myles | COO & CFO | 255,189 | $25.88 | $6.7B | -10.28% | +104.69% | $6.6M | -1.97% | 10b5-1 | Buy Now |
| Feb 18, 2025 | Sell | SRRK | Caryn Parlavecchio | CHRO | 5,296 | $36.83 | $6.7B | -10.28% | +104.69% | $195.0K | -3.64% | — | Buy Now |
| Feb 18, 2025 | Sell | SRRK | Junlin Ho | GENERAL COUNSEL | 5,742 | $36.83 | $6.7B | -10.28% | +104.69% | $211.5K | -2.94% | — | Buy Now |
| Feb 18, 2025 | Sell | SRRK | Edward H Myles | COO & CFO | 7,809 | $36.83 | $6.7B | -10.28% | +104.69% | $287.6K | -5.26% | — | Buy Now |
| Feb 18, 2025 | Sell | SRRK | Jay T. Backstrom | CHIEF EXECUTIVE OFFICER | 18,372 | $36.83 | $6.7B | -10.28% | +104.69% | $676.6K | -5.56% | — | Buy Now |
| Feb 18, 2025 | Sell | SRRK | Mo Qatanani | CHIEF SCIENTIFIC OFFICER | 120,953 | $26.51 | $6.7B | -10.28% | +104.69% | $3.2M | -1.89% | 10b5-1 | Buy Now |
| Jan 16, 2025 | Sell | SRRK | Tracey Sacco | Chief Commercial Officer | 3,890 | $44.20 | $6.7B | -10.28% | +104.69% | $171.9K | -7.89% | — | Buy Now |
| Jan 16, 2025 | Sell | SRRK | Jing L. Marantz | CHIEF MEDICAL OFFICER | 5,655 | $44.20 | $6.7B | -10.28% | +104.69% | $249.9K | -7.76% | — | Buy Now |
| Jan 16, 2025 | Sell | SRRK | Caryn Parlavecchio | CHRO | 6,434 | $44.20 | $6.7B | -10.28% | +104.69% | $284.4K | -4.23% | — | Buy Now |
| Jan 16, 2025 | Sell | SRRK | Mo Qatanani | CHIEF SCIENTIFIC OFFICER | 7,347 | $44.20 | $6.7B | -10.28% | +104.69% | $324.7K | -5.15% | — | Buy Now |
| Jan 16, 2025 | Sell | SRRK | Junlin Ho | GENERAL COUNSEL | 9,039 | $44.20 | $6.7B | -10.28% | +104.69% | $399.5K | -4.43% | — | Buy Now |
| Jan 16, 2025 | Sell | SRRK | Edward H Myles | COO & CFO | 12,539 | $44.20 | $6.7B | -10.28% | +104.69% | $554.2K | -7.78% | — | Buy Now |
| Jan 16, 2025 | Sell | SRRK | Jay T. Backstrom | CHIEF EXECUTIVE OFFICER | 22,308 | $44.20 | $6.7B | -10.28% | +104.69% | $986.0K | -6.33% | — | Buy Now |
| Nov 22, 2024 | Sell | SRRK | Jing L. Marantz | CHIEF MEDICAL OFFICER | 17,040 | $22.83 | $6.7B | -10.28% | +104.69% | $389.0K | +0.00% | 10b5-1 | Buy Now |
| Nov 11, 2024 | Sell | SRRK | Jing L. Marantz | CHIEF MEDICAL OFFICER | 4,210 | $19.30 | $6.7B | -10.28% | +104.69% | $81.2K | +0.00% | 10b5-1 | Buy Now |
| Oct 8, 2024 | Sell | SRRK | Edward H Myles | COO & CFO | 74,374 | $22.45 | $6.7B | -10.28% | +104.69% | $1.7M | +0.00% | 10b5-1 | Buy Now |
| Oct 7, 2024 | Sell | SRRK | Tracey Sacco | CHIEF COMMERCIAL OFFICER | 60,000 | $17.81 | $6.7B | -10.28% | +104.69% | $1.1M | +0.00% | 10b5-1 | Buy Now |
| Oct 7, 2024 | Sell | SRRK | Jing L. Marantz | CHIEF MEDICAL OFFICER | 218,750 | $17.90 | $6.7B | -10.28% | +104.69% | $3.9M | +0.00% | 10b5-1 | Buy Now |
| Oct 7, 2024 | Sell | SRRK | Edward H Myles | COO & CFO | 412,480 | $20.19 | $6.7B | -10.28% | +104.69% | $8.3M | +0.00% | 10b5-1 | Buy Now |
| Sep 16, 2024 | Sell | SRRK | Mo Qatanani | CHIEF SCIENTIFIC OFFICER | 1,936 | $8.58 | $6.7B | -10.28% | +104.69% | $16.6K | -1.34% | — | Buy Now |
| Aug 16, 2024 | Sell | SRRK | Caryn Parlavecchio | CHRO | 1,451 | $9.33 | $6.7B | -10.28% | +104.69% | $13.5K | -0.95% | — | Buy Now |
| Jun 17, 2024 | Sell | SRRK | Mo Qatanani | CHIEF SCIENTIFIC OFFICER | 2,315 | $8.98 | $6.7B | -10.28% | +104.69% | $20.8K | -1.57% | — | Buy Now |
| Jun 17, 2024 | Sell | SRRK | Caryn Parlavecchio | CHRO | 4,305 | $8.98 | $6.7B | -10.28% | +104.69% | $38.7K | -2.73% | — | Buy Now |
| Jun 17, 2024 | Sell | SRRK | Junlin Ho | GENERAL COUNSEL | 4,695 | $8.98 | $6.7B | -10.28% | +104.69% | $42.2K | -2.25% | — | Buy Now |
| Jun 17, 2024 | Sell | SRRK | Edward H Myles | COO & CFO | 9,458 | $8.98 | $6.7B | -10.28% | +104.69% | $85.0K | -4.48% | — | Buy Now |
| Feb 16, 2024 | Sell | SRRK | Mo Qatanani | CHIEF SCIENTIFIC OFFICER | 2,512 | $15.74 | $6.7B | -10.28% | +104.69% | $39.5K | -1.68% | — | Buy Now |
| Feb 16, 2024 | Sell | SRRK | Junlin Ho | GENERAL COUNSEL | 3,489 | $15.74 | $6.7B | -10.28% | +104.69% | $54.9K | -1.64% | — | Buy Now |
| Feb 16, 2024 | Sell | SRRK | Caryn Parlavecchio | CHRO | 3,751 | $15.74 | $6.7B | -10.28% | +104.69% | $59.1K | -2.32% | — | Buy Now |
| Feb 16, 2024 | Sell | SRRK | Edward H Myles | COO & CFO | 4,744 | $15.74 | $6.7B | -10.28% | +104.69% | $74.7K | -2.20% | — | Buy Now |
| Feb 16, 2024 | Sell | SRRK | Jay T. Backstrom | CHIEF EXECUTIVE OFFICER | 11,614 | $15.74 | $6.7B | -10.28% | +104.69% | $182.8K | -3.19% | — | Buy Now |
| Jan 16, 2024 | Sell | SRRK | Mo Qatanani | SVP AND HEAD OF RESEARCH | 2,002 | $15.93 | $6.7B | -10.28% | +104.69% | $31.9K | -2.48% | — | Buy Now |
| Jan 16, 2024 | Sell | SRRK | Caryn Parlavecchio | CHRO | 2,849 | $15.93 | $6.7B | -10.28% | +104.69% | $45.4K | -2.43% | — | Buy Now |
| Jan 16, 2024 | Sell | SRRK | Junlin Ho | GENERAL COUNSEL | 4,186 | $15.93 | $6.7B | -10.28% | +104.69% | $66.7K | -2.64% | — | Buy Now |
| Jan 16, 2024 | Sell | SRRK | Edward H Myles | COO & CFO | 6,634 | $15.93 | $6.7B | -10.28% | +104.69% | $105.7K | -3.93% | — | Buy Now |
| Dec 29, 2023 | Sell | SRRK | Edward H Myles | COO & CFO | 24,918 | $11.85 | $6.7B | -10.28% | +104.69% | $295.2K | +0.00% | 10b5-1 | Buy Now |
| Dec 14, 2023 | Sell | SRRK | Mo Qatanani | SVP AND HEAD OF RESEARCH | 33,099 | $16.10 | $6.7B | -10.28% | +104.69% | $532.8K | -6.79% | — | Buy Now |
| Dec 7, 2023 | Sell | SRRK | Edward H Myles | COO & CFO | 49,828 | $11.20 | $6.7B | -10.28% | +104.69% | $557.9K | +0.00% | 10b5-1 | Buy Now |
| Nov 2, 2023 | Sell | SRRK | Edward H Myles | COO & CFO | 35,007 | $12.51 | $6.7B | -10.28% | +104.69% | $438.0K | -17.18% | 10b5-1 | Buy Now |
| Sep 18, 2023 | Sell | SRRK | Mo Qatanani | SVP AND HEAD OF RESEARCH | 1,945 | $6.34 | $6.7B | -10.28% | +104.69% | $12.3K | -1.96% | — | Buy Now |